智通财经网·2026-01-20 12:08Group 1 - The company expects to achieve operating revenue of approximately RMB 1.573 billion to RMB 1.738 billion in 2025, representing a decrease of about RMB 280 million to RMB 446 million compared to the previous year, which is a year-on-year decline of approximately 13.9% to 22.1% [1] - The projected net profit attributable to shareholders for 2025 is expected to be around RMB 233 million to RMB 349 million, an increase of approximately RMB 159 million to RMB 275 million compared to the previous year, reflecting a year-on-year increase of about 214.0% to 371.0% [1] - The expected net profit attributable to shareholders after deducting non-recurring gains and losses is projected to be approximately RMB 246 million to RMB 370 million, which is an increase of about RMB 223 million to RMB 346 million year-on-year, indicating a significant increase of approximately 945.2% to 1,467.7% [1] Group 2 - The increase in the fair value of biological assets is driven by rising market prices and natural growth, contributing positively to the company's performance [2] - The laboratory services segment continues to operate steadily; however, revenue and gross margin from performance contracts have decreased year-on-year due to prior intense industry competition, leading to a decline in profit contribution from laboratory services [2]